993 related articles for article (PubMed ID: 9147701)
1. Secretion of both IL-2 and IL-4 by tumor cells results in rejection and immunity.
Strome SE; Chang AE; Shu S; Krauss JC
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):21-32. PubMed ID: 9147701
[TBL] [Abstract][Full Text] [Related]
2. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
3. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
4. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
5. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
[TBL] [Abstract][Full Text] [Related]
6. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
8. Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Collins MK; Cohen EP
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):298-304. PubMed ID: 7904182
[TBL] [Abstract][Full Text] [Related]
9. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
10. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
[TBL] [Abstract][Full Text] [Related]
11. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
12. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
13. Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Chang AE
J Immunother; 1997 Mar; 20(2):138-45. PubMed ID: 9087386
[TBL] [Abstract][Full Text] [Related]
14. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.
Bishop DK; Chan Wood S; Eichwald EJ; Orosz CG
J Immunol; 2001 Mar; 166(5):3248-55. PubMed ID: 11207279
[TBL] [Abstract][Full Text] [Related]
15. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
16. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.
Kim TS; Cohen EP
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):24-35. PubMed ID: 8081557
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
Krauss JC; Strome SE; Chang AE; Shu S
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
19. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
20. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
